Moleculin Biotech Files 8-K Report
Ticker: MBRX · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1659617
| Field | Detail |
|---|---|
| Company | Moleculin Biotech, Inc. (MBRX) |
| Form Type | 8-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Moleculin Biotech filed an 8-K, mostly standard financial disclosures.
AI Summary
On April 29, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and also includes a Regulation FD Disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Moleculin Biotech is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- April 29, 2025 (date) — Date of Report
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Moleculin Biotech, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD Disclosure.
What is the filing date of this 8-K report?
The filing date of this 8-K report is April 29, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is Moleculin Biotech, Inc.'s Commission File Number?
Moleculin Biotech, Inc.'s Commission File Number is 001-37758.
What is the Standard Industrial Classification code for Moleculin Biotech, Inc.?
The Standard Industrial Classification code for Moleculin Biotech, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Moleculin Biotech, Inc. (MBRX).